

Supplementary Materials

Characterization of Regulatory and Transporter Genes in the Biosynthesis of Anti-Tuberculosis Ilamycins and Production in a Heterologous Host

Jianqiao He^{1,3}, Xin Wei^{1,3}, Zhijie Yang^{1,3}, Yan Li,¹ Jianhua Ju^{1,2,3} and Junying Ma^{1,2*}

¹ CAS Key Laboratory of Tropical Marine Bio-resources and Ecology, Guangdong Key Laboratory of Marine Materia Medica, RNAM Center for Marine Microbiology, South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou, 510301, China; weixin1011@126.com (X.W.); 13409727100@163.com (J.H.); yzjie6@126.com (Z.Y.)

² Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou).

³ University of Chinese Academy of Sciences, Beijing, 100049, China.

* Correspondence: majunying@scsio.ac.cn; Tel.: (+86)20-34066449 (J.M.)

Received: 20 March 2020; Accepted: 14 April 2020; Published: 17 April 2020

Item Name	Contents/Description	Page
Table S1	Summary of strains and plasmids used in this study.	S2
Table S2	Summary of primers used in this study.	S3
Figure S1	Disruption of <i>ilaA</i> in <i>S. atratus</i> SCSIO ZH16.	S4
Figure S2	Disruption of <i>ilaB</i> in <i>S. atratus</i> SCSIO ZH16.	S4
Figure S3	Sequence alignment of IlaJ with its homologues.	S5
Figure S4	Secondary structure prediction of transmembrane region of IlaK with TMHMM V2.0 and primary sequence alignment of IlaK with its homologues from the genus <i>Streptomyces</i> .	S6
Figure S5	Disruption of <i>ilaJ</i> in <i>S. atratus</i> SCSIO ZH16.	S7
Figure S6	Disruption of <i>ilaK</i> in <i>S. atratus</i> SCSIO ZH16.	S7
Figure S7	Disruption of <i>ilaJk</i> in <i>S. atratus</i> SCSIO ZH16.	S8
Figure S8	The quantitative HPLC standard curve for ilamycin D.	S8
Figure S9	The PCR verification of PAC-7A6 containing entire <i>ila</i> gene cluster.	S9
Reference		S9

Table 1. Summary of strains and plasmids used in this study.

Strains/ plasmids	Relevant phenotype	Source/ [Ref]
<i>S. atratus</i> SCSIO ZH16	Wild-type (WT) producer of ilamycin	[1]
<i>S. coelicolor</i> M1152		[2]
$\Delta ilaA$	<i>S. atratus</i> SCSIO ZH16 with a 296 bp of <i>ilaA</i> substituted by <i>aac(3)IV+OriT</i>	This work
$\Delta ilaB$	<i>S. atratus</i> SCSIO ZH16 with a 816 bp of <i>ilaB</i> substituted by <i>aac(3)IV+OriT</i>	This work
$\Delta ilaJ$	<i>S. atratus</i> SCSIO ZH16 with a 723 bp of <i>ilaJ</i> substituted by <i>aac(3)IV+OriT</i>	This work
$\Delta ilaK$	<i>S. atratus</i> SCSIO ZH16 with a 471 bp of <i>ilaK</i> substituted by <i>aac(3)IV+OriT</i>	This work
$\Delta ilaJK$	<i>S. atratus</i> SCSIO ZH16 with a 1502 bp of <i>ilaJ</i> and <i>ilaK</i> substituted by <i>aac(3)IV+OriT</i>	
<i>E. coli</i>		
Bw25113	K-12 derivative: <i>araBAD</i> , <i>rhaBAD</i>	[3]
ET12567	<i>dam</i> , <i>dcm</i> , <i>hsdM</i> , <i>hsdS</i> , <i>hsdR</i> , <i>catR</i> , <i>tetR</i>	[4]
Plasmids		
pIJ773	P1-FRT-oriT- <i>aac(3)IV-FRT-P2</i>	[5]
pIJ790	λ -RED (<i>gam bet exo</i>) CmlR <i>araCrep101ts</i>	[5]
pUZ8002	<i>tra</i> , <i>neo</i> , RP4	[6]
pL646ATE	<i>Tsr</i> , <i>acc(3)IV</i> , <i>ermE*P</i>	[7]
cosmid-23D	A cosmid which contains partial ilamycin biosynthetic gene cluster	This work
cosmid-42G	A cosmid which contains partial ilamycin biosynthetic gene cluster	This work
PAC-7A6	A cosmid which contains complete ilamycin biosynthetic gene cluster	This work
$p\Delta ilaA$	A 296 bp fragment in <i>ilaA</i> in cosmid 23D was substituted by the <i>aac(IV)+OriT</i> cassette using the PCR-targeting strategy	This work
$p\Delta ilaB$	A 816 bp fragment in <i>ilaB</i> in cosmid 23D was substituted by the <i>aac(IV)+OriT</i> cassette using the PCR-targeting strategy	This work
$p\Delta ilaJ$	A 723 bp fragment in <i>ilaJ</i> in cosmid 42G was substituted by the <i>aac(IV)+OriT</i> cassette using the PCR-targeting strategy	This work
$p\Delta ilaK$	A 471 bp fragment in <i>ilaK</i> in cosmid 42G was substituted by the <i>aac(IV)+OriT</i> cassette using the PCR-targeting strategy	This work
$p\Delta ilaJK$	A 1502 bp fragment in <i>ilaJ</i> and <i>ilaK</i> substituted by the <i>aac(IV)+OriT</i> cassette using the PCR-targeting strategy	This work
$\Delta ilaB::ilaB$	An integrated vector pL646ATE with complete <i>ilaB</i> for complementation of $\Delta ilaB$ mutant	This work
<i>S. atratus</i> ZH16: <i>ilaB</i>	An integrated vector pL646ATE with complete <i>ilaB</i> for over-expression	This work

Table S2 the primers were used for gene inactivation and verification.

Primer name	The sequence (5'-3')	purpose
DelilaAF	GTGCTGACGAATGCCCTGTACAGGATCTCATCTTG ACA ATTCCGGGATCCGTCACC	For disrupting <i>ilaA</i>
DelilaAR	TCACCGGCCGAACCGCGTAAACGGAATCAGGC GCCGCTGTAGGCTGGAGCTGCTTC	
DelilaBF	GACGTGCCGGACGGGGCAGCGGACGGGTACGT CCTCG ATTCCGGGATCCGTCACC	For disrupting <i>ilaB</i>
DelilaBR	GAGACGGGCCACGACCTCTGACGGTGAGGCGGG ACCGCTGTAGGCTGGAGCTGCTTC	
DelilaJF	GCCGTCGACGGCCTCGATCTGGCGTCCC GGCG TGCC ATTCCGGGATCCGTCACC	For disrupting <i>ilaJ</i>
DelilaJR	GACGGTCTGGGTGAGTTGCCAGCGCACGCCA CGCTGTAGGCTGGAGCTGCTTC	
DelilaKF	GTCGAGGCGGACGAGAGGCTGCGCCGGTCCTGG GTGAG ATTCCGGGATCCGTCACC	For disrupting <i>ilaK</i>
DelilaKR	CGCGCAGCACCAAGGCCGAGGAACGTCCAGATCCAC GAGACT GTAGGCTGGAGCTGCTTC	
IDilaAF	AGGGTCATCATCGCTGTCTCG	For verifying mutant of $\Delta ilaA$
IDilaAR	CGGCATGGGTTTCAATCTAC	
IDilaBF	CGACGGGTCACAACATCCT	For verifying mutant of $\Delta ilaB$
IDilaBR	CATTCTCCGACGCACGATC	
IDilaJF	GCGAACCTAACGGTGAATGTG	For verifying mutant of $\Delta ilaJ$
IDilaJR	GGTCAGGGGAGGAACAC	
IDilaKF	ACGACGACCGAGGGAGACCC	For verifying mutant of $\Delta ilaK$
IDilaKR	CGAATGCCCTCAGCCACCC	
Com-ilaB-F	aaaacatgATGATCGGTAGATTGAAAGCCATGC	For complete cloning the <i>ilaB</i>
Com-ilaB-R	aaaaactgtggatccTCACCCCGCCTCCGTG	
orf(-2) F	CGGTGCGTGTGAGATCCTGT	For verification of the heterologues expression conjugants
orf(-2)R	TCGAACCTCCGAGCAAACG	
<i>ilaNF</i>	CCGCTGCCGTCTTCATCG	For verification of the heterologues expression conjugants
<i>ilaNR</i>	TGAGTCGTCGCCGCCCTTC	
orf(+2)F	ACAGAGCGGATTCCGTGGTG	For verification of the heterologues expression conjugants
orf(+2)R	AGCGATTTGTGGGTTCAAGG	




Figure S1. Disruption of *ilaA* in wild type *S. atratus* SCSIO ZH16 via PCR-targeting. (A) Schematic representation for disruption of *ilaA*. (B) PCR analyses of the WT strain and the *ilaA* double-cross mutant carried out using the primers listed in Table S2. M: DNA molecular ladder; WT: using the genomic DNA of *S. atratus* SCSIO ZH16 as template; Δ *ilaA*-1-3: using the genomic DNA of *ilaA* mutant as template.




Figure S2. Disruption of *ilaB* in wild type *S. atratus* SCSIO ZH16 via PCR-targeting. (A) Schematic representation for disruption of *ilaB*. (B) PCR analyses of the WT strain and the *ilaB* double-cross mutant carried out using the primers listed in Table S2. M: DNA molecular ladder; WT: using the genomic DNA of *S. atratus* SCSIO ZH16 as template; Δ *ilaB*-1-3: using the genomic DNA of *ilaB* mutant as template.




Figure S3. The primary sequence alignment of IlaJ and its homologues from other strains including MtrA (GenBank accession no. CAK50797) from *Streptomyces argillaceus*, Atr29 (GenBank accession no. QBG38790.1) from *S. atratus* SCSIO ZH16, DrrA (GenBank accession no. ATW50556.1) from *Streptomyces peucetius subsp. caesius* ATCC 27952. The predicted Walker A, Walker B, the ABC signature motif, the Q-loop, the D-loop and the switch region were marked with fluorescent green box, cyan box, blue box and black box.




Figure S4. Secondary structure prediction of transmembrane region of IlaK with TMHMM V2.0 and primary sequence alignment of IlaK with its homologues from the genus *Streptomyces*. A) the protein length of IlaK; B) the transmembrane region of IlaK; C) the sequence alignment of IlaK with its homologues including TnrB3 (GenBank accession no. CAA52013) from *Streptomyces longisporoflavus*, MtrB (GenBank accession no. CAK50798) from *Streptomyces argillaceus*, Atr30 (GenBank accession no. QBG38791) from *Streptomyces atratus* SCSIO ZH16, DrrB (GenBank accession no. AAA74718) from *Streptomyces peucetius*. Different color box represents different transmembrane region. The fluorescent blue box indicates the inside region, the fluorescent pink box indicates outside region and the fluorescent green indicates the transmembrane region. The two marked motifs were proposed functional similar to the conserved “EAA motif” of importers.




Figure S5. Disruption of *ilaj* in wild type *S. atratus* SCSIO ZH16 via PCR-targeting. (A) Schematic representation for disruption of *ilaj*. (B) PCR analyses of the WT strain and the *ilaj* double-cross mutant carried out using the primers listed in Table S2. M: DNA molecular ladder; WT: using the genomic DNA of *S. atratus* SCSIO ZH16 as template; Δ *ilaj*-1-3: using the genomic DNA of *ilaj* mutant as template.




Figure S6. Disruption of *ilaK* in wild type *S. atratus* SCSIO ZH16 via PCR-targeting. (A) Schematic representation for disruption of *ilaK*. (B) PCR analyses of the WT strain and the *ilaK* double-cross mutant carried out using the primers listed in Table S2. M: DNA molecular ladder; WT: using the genomic DNA of *S. atratus* SCSIO ZH16 as template; Δ *ilaK*-1-3: using the genomic DNA of *ilaK* mutant as template.




Figure S7. Disruption of *ilaJK* in wild type *S. atratus* SCSIO ZH16 via PCR-targeting. (A) Schematic representation for disruption of *ilaJK*. (B) PCR analyses of the WT strain and the *ilaJK* double-cross mutant carried out using the primers listed in Table S2. M: DNA molecular ladder; WT: using the genomic DNA of *S. atratus* SCSIO ZH16 as template; Δ *ilaJK*-1-3: using the genomic DNA of *ilaJK* mutant as template.




Figure S8. The standard curve of ilamycin D based on HPLC analysis.




Figure S9. The PCR verification of the *ila* BGC heterologous expression conjugants with three pairs of primers listed in Table S2. M: DL2000 marker, 1-3: using the genomic DNA of the *ila* BGC successfully expressed conjugants as template.

References

1. Ma, J.; Huang, H.; Xie, Y.; Liu, Z.; Zhao, J.; Zhang, C.; Jia, Y.; Zhang, Y.; Zhang, H.; Zhang, T. Biosynthesis of ilamycins featuring unusual building blocks and engineered production of enhanced anti-tuberculosis agents. *Nat. Commun.* **2017**, *8*, 391.
2. Gomez-Escribano, J. P.; Bibb, M. J. Engineering *Streptomyces coelicolor* for heterologous expression of secondary metabolite gene clusters. *Microb. Biotechnol.* **2011**, *4*, 207–215.
3. Macneil, D. J.; Gewain, K. M.; Ruby, C. L.; Dezeny, G.; Gibbons, P. H.; Macneil, T., Analysis of *Streptomyces avermitilis* genes required for avermectin biosynthesis utilizing a novel integration vector. *Gene* **1992**, *111*, 61–68.
4. Datsenko, K. A.; Wanner, B. L., One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Nat. Acad. Sci. U S A* **2000**, *97*, 6640–6645.
5. Gust, B.; Chandra, G.; Jakimowicz, D.; Tian, Y. Q.; Bruton, C. J.; Chater, K. F., lambda red-mediated genetic manipulation of antibiotic-producing *Streptomyces*. *Adv. Appl. Microbiol.* **2004**, *54*, 107–128.
6. Paget, M. S. B.; Chamberlin, L.; Atri, A.; Foster, S. J.; Buttner, M. J., Evidence that the extracytoplasmic function sigma factor sigma (E) is required for normal cell wall structure in *Streptomyces coelicolor* A3(2). *J. Bacteriol.* **1999**, *181*, 204–211.
7. Tu, J.; Li, S.; Chen, J.; Song, Y.; Fu, S.; Ju, J.; Li, Q., Characterization and heterologous expression of the neoabyssomicin/abyssomicin biosynthetic gene cluster from *Streptomyces koyangensis* SCSIO 5802. *Microbial Cell Factories* **2018**, *17*, 1–14.